Sign in for the best experience.
Biologic agents have become a standard of care in patients unresponsive to usual treatments, yet the choice of biologic agent is complex. This guideline examines the literature related to choice of biologic agent in patients with severe asthma and consists of seven evidence-based recommendations to optimize their use.
ACCESS THE FULL GUIDELINE
In adult patients with severe allergic asthma and ≥ one exacerbation per year, we suggest either omalizumab or dupilumab.
In adult patients with severe asthma who are steroid dependent, we suggest either anti-IL-5/5Ra or dupilumab.
In adult patients with severe asthma who have not demonstrated a clinical response to anti-IL-5/5Ra therapy after four to six months, we suggest either dupilumab or tezepelumab.
Advertisement
Our guidelines are aimed at helping you respond to today’s clinical challenges and improve patient health outcomes. Our panel of experts has developed multimedia content to facilitate adoption of this guideline into your day-to-day practice.
CHEST Releases Guideline on Biologic Management in Severe Asthma In a release issued to the media, lead author Amber J. Oberle, MD, speaks to the importance of this guideline in practice.
CHEST offers education, networking opportunities, and articles on asthma.
This Network educates clinicians about airways disorders, including asthma, COPD, pediatric medicine, and more.
Access the best of CHEST's asthma learning resources, and claim up to 20.75 hours of credit—all in one place, via web and mobile device.
Sign up for expert-led, hands-on simulation courses offering training in diagnostic bronchoscopy, pleural procedures, and more.